IL177724A - Methods for reducing the degree of aggregation of aggregating cells in a cell culture - Google Patents
Methods for reducing the degree of aggregation of aggregating cells in a cell cultureInfo
- Publication number
- IL177724A IL177724A IL177724A IL17772406A IL177724A IL 177724 A IL177724 A IL 177724A IL 177724 A IL177724 A IL 177724A IL 17772406 A IL17772406 A IL 17772406A IL 177724 A IL177724 A IL 177724A
- Authority
- IL
- Israel
- Prior art keywords
- cells
- cell culture
- cell
- perfusion
- per
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 44
- 238000004113 cell culture Methods 0.000 title claims description 33
- 230000004931 aggregating effect Effects 0.000 title claims description 15
- 230000002776 aggregation Effects 0.000 title claims description 10
- 238000004220 aggregation Methods 0.000 title claims description 10
- 210000004027 cell Anatomy 0.000 claims description 171
- 230000010412 perfusion Effects 0.000 claims description 59
- 238000012258 culturing Methods 0.000 claims description 31
- 239000002028 Biomass Substances 0.000 claims description 20
- 239000006143 cell culture medium Substances 0.000 claims description 20
- 239000012510 hollow fiber Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 10
- 238000000926 separation method Methods 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 238000011143 downstream manufacturing Methods 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 239000000813 peptide hormone Substances 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 description 22
- 230000014759 maintenance of location Effects 0.000 description 10
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229960000074 biopharmaceutical Drugs 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000005253 yeast cell Anatomy 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical group OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- -1 D-panthothenate Chemical compound 0.000 description 1
- 101150029662 E1 gene Proteins 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000013266 Human Regular Insulin Human genes 0.000 description 1
- 108010090613 Human Regular Insulin Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000081271 Phaffia rhodozyma Species 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 229940124942 Recombivax HB Drugs 0.000 description 1
- 108700033496 Recombivax HB Proteins 0.000 description 1
- 229940124859 Rotavirus vaccine Drugs 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940105774 coagulation factor ix Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- SQNZJJAZBFDUTD-UHFFFAOYSA-N durene Chemical compound CC1=CC(C)=C(C)C=C1C SQNZJJAZBFDUTD-UHFFFAOYSA-N 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940089118 epogen Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 108010006578 follitropin alfa Proteins 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940057854 gonal f Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 229940103471 humulin Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940038490 inactivated hepatitis a vaccine Drugs 0.000 description 1
- 229940090438 infergen Drugs 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940047434 kogenate Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 229940063137 norditropin Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 108700031632 somatrem Proteins 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
- C12M3/06—Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/10—Hollow fibers or tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/10—Perfusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/44—Means for regulation, monitoring, measurement or control, e.g. flow regulation of volume or liquid level
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Sustainable Development (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Virology (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Water Supply & Treatment (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04075702 | 2004-03-05 | ||
| EP04075703 | 2004-03-05 | ||
| EP04077656 | 2004-09-27 | ||
| EP04077657 | 2004-09-27 | ||
| PCT/EP2005/002374 WO2005095578A1 (en) | 2004-03-05 | 2005-03-04 | Process for cell culturing by continuous perfusion and alternating tangential flow |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL177724A0 IL177724A0 (en) | 2006-12-31 |
| IL177724A true IL177724A (en) | 2011-01-31 |
Family
ID=34961830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL177724A IL177724A (en) | 2004-03-05 | 2006-08-28 | Methods for reducing the degree of aggregation of aggregating cells in a cell culture |
| IL205606A IL205606A (en) | 2004-03-05 | 2010-05-06 | Perfusion cultures comprising a cell culture medium and aggregating animal cells |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL205606A IL205606A (en) | 2004-03-05 | 2010-05-06 | Perfusion cultures comprising a cell culture medium and aggregating animal cells |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8206981B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP1720972B1 (cg-RX-API-DMAC7.html) |
| JP (6) | JP2007525984A (cg-RX-API-DMAC7.html) |
| KR (1) | KR101050585B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN104388324A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005229359C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2557046A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1720972T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2456015T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL177724A (cg-RX-API-DMAC7.html) |
| PL (1) | PL1720972T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1720972E (cg-RX-API-DMAC7.html) |
| SI (1) | SI1720972T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005095578A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1720972B1 (en) | 2004-03-05 | 2014-01-08 | DSM IP Assets B.V. | Process for cell culturing by continuous perfusion and alternating tangential flow |
| CN104131038A (zh) | 2006-02-24 | 2014-11-05 | 东丽株式会社 | 化学品的制备方法和连续发酵装置 |
| EP1870450A1 (en) * | 2006-06-21 | 2007-12-26 | DSMIP Assets B.V. | Process for the culturing of E1-immortalized HER cells |
| AU2011211462C1 (en) * | 2006-07-14 | 2015-01-22 | Dpx Holdings B.V. | Improved process for the culturing of cells |
| PL2343362T5 (pl) | 2006-07-14 | 2024-12-02 | Patheon Holdings I B.V. | Ulepszony proces hodowli komórek |
| EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
| PT2574677T (pt) * | 2007-12-27 | 2017-10-19 | Baxalta Inc | Processos para cultura de células |
| WO2010003759A2 (en) * | 2008-06-17 | 2010-01-14 | Dsm Ip Assets B.V. | Cell culturing method |
| EP2334783B1 (en) | 2008-09-02 | 2016-06-22 | Pluristem Ltd. | Adherent cells from placenta tissue and use thereof in therapy |
| DK2350268T3 (en) * | 2008-11-03 | 2015-03-23 | Crucell Holland Bv | PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS |
| MA33429B1 (fr) | 2009-07-16 | 2012-07-03 | Crucell Holland Bv | Production de poliovirus à titres élevés pour la production de vaccins |
| KR101805938B1 (ko) | 2009-10-15 | 2018-01-10 | 얀센 백신스 앤드 프리벤션 비.브이. | 고밀도 세포 배양액에서 아데노바이러스의 정제 방법 |
| CN102791852B (zh) | 2009-10-15 | 2014-05-07 | 克鲁塞尔荷兰公司 | 纯化腺病毒颗粒的方法 |
| EP3255153A1 (en) | 2009-11-17 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Methods for enhanced protein production |
| US20120315696A1 (en) * | 2010-02-15 | 2012-12-13 | Alfred Luitjens | METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS |
| KR101820980B1 (ko) * | 2010-02-15 | 2018-01-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Ａｄ 26 아데노바이러스 벡터를 제조하는 방법 |
| WO2011144561A1 (en) | 2010-05-18 | 2011-11-24 | Crucell Holland B.V. | Methods for welding ethylene vinyl acetate (eva) tubing, tubing obtained thereby and use of such tubing for sterile transfer of content into a bioreactor |
| US10138290B2 (en) | 2010-10-05 | 2018-11-27 | Novo Nordisk Healthcare Ag | Process for protein production |
| DK3626737T3 (da) * | 2011-05-13 | 2024-02-05 | Octapharma Ag | Fremgangsmåde til at forøge produktiviteten af eukaryote celler i produktionen af rekombinant fviii |
| LT2837680T (lt) * | 2011-07-01 | 2020-07-10 | Amgen Inc. | Žinduolių ląstelių kultūra |
| CN104010654B (zh) | 2011-10-18 | 2017-10-27 | 科荣生生物科学公司 | 金属离子稳定的依那西普制剂 |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| CN103305417A (zh) * | 2012-03-07 | 2013-09-18 | 无锡药明康德生物技术有限公司 | 进行蛋白生产的高产量反应器及其生产方法和应用 |
| GB201211256D0 (en) | 2012-06-25 | 2012-08-08 | Glaxosmithkline Biolog Sa | Fermentation process |
| HK1209343A1 (en) | 2012-07-09 | 2016-04-01 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
| HRP20180182T1 (hr) | 2012-09-11 | 2018-04-20 | Coherus Biosciences, Inc. | Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa |
| EP2900804B1 (en) * | 2012-09-27 | 2019-09-18 | GE Healthcare Bio-Sciences AB | Tangential flow perfusion system |
| TWI637057B (zh) | 2012-11-09 | 2018-10-01 | 拜爾沙納有限公司 | 具交替生物反應器用途之不連續進料批次製程 |
| CA2906600A1 (en) * | 2013-03-15 | 2014-09-18 | Genzyme Corporation | High-density cell banking methods |
| DK2976418T3 (da) | 2013-03-19 | 2021-01-11 | Cmc Biologics As | Fremgangsmåde til fremstilling af et produkt (f.eks. polypeptid) i en kontinuerlig cellekulturfermenteringsproces |
| CA2907771C (en) * | 2013-03-26 | 2023-01-10 | Coherus Biosciences, Inc. | Perfusion method for manufacturing etanercept |
| US9790465B2 (en) | 2013-04-30 | 2017-10-17 | Corning Incorporated | Spheroid cell culture well article and methods thereof |
| CN105722967B (zh) * | 2013-09-16 | 2021-03-19 | 建新公司 | 用于处理细胞培养物的方法和系统 |
| US10421986B2 (en) | 2013-09-30 | 2019-09-24 | Janssen Vaccines & Prevention B.V. | Method for the clarification of high-density crude cell culture harvest |
| CN103525756B (zh) * | 2013-10-23 | 2015-04-08 | 南京农业大学 | 一种原代鸡肝细胞的分离培养方法 |
| EP3083933A1 (en) * | 2013-12-20 | 2016-10-26 | Biogen MA Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
| AU2014380174C1 (en) * | 2014-01-29 | 2025-06-05 | Amgen Inc. | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
| BR112016018797A8 (pt) * | 2014-02-17 | 2020-06-23 | Advantech Bioscience Farm Ltda | aperfeiçoamento de expressão de proteína recombinante com o uso de um sistema de retenção de célula baseado em membrana |
| US11384378B2 (en) * | 2014-06-04 | 2022-07-12 | Amgen Inc. | Methods for harvesting mammalian cell cultures |
| US10294460B2 (en) | 2014-07-24 | 2019-05-21 | Janssen Vaccines & Prevention B.V. | Process for the purification of poliovirus from cell cultures |
| JP6530171B2 (ja) * | 2014-09-09 | 2019-06-12 | 旭化成メディカル株式会社 | 培養産生物の回収方法 |
| KR20240005197A (ko) * | 2014-09-18 | 2024-01-11 | 젠자임 코포레이션 | 초고밀도 세포 뱅킹 방법 |
| EP3212760A1 (en) | 2014-10-29 | 2017-09-06 | Corning Incorporated | Perfusion bioreactor platform |
| KR102460969B1 (ko) | 2014-10-29 | 2022-10-31 | 코닝 인코포레이티드 | 세포 배양 인서트 |
| WO2016069930A1 (en) | 2014-10-29 | 2016-05-06 | Corning Incorporated | Microwell design and fabrication for generation of cell culture aggregates |
| WO2016073858A1 (en) | 2014-11-07 | 2016-05-12 | Genesis Technologies, Llc | Linear reciprocating actuator |
| BR112017013423B1 (pt) | 2014-12-22 | 2023-04-11 | Genzyme Corporation | Métodos para cultivo de célula de mamífero |
| CN107532132A (zh) * | 2015-02-09 | 2018-01-02 | 优尼沃赛尔斯公司 | 用于生产细胞和/或细胞产品的系统、装置和方法 |
| WO2017180724A1 (en) * | 2016-04-12 | 2017-10-19 | Artemis Biosystems, Inc. | Perfusion filtration systems |
| EP3442986A4 (en) * | 2016-04-14 | 2019-11-13 | Trizell Ltd. | FIXED BAYOR ACTUATOR WITH CONSTANT FLOW PUMP / PIPING SYSTEM |
| US11261416B2 (en) | 2016-04-14 | 2022-03-01 | Trizell Ltd. | Fixed-bed bioreactor with constant-flow pump / tubing system |
| KR102414290B1 (ko) | 2016-04-15 | 2022-06-29 | 베링거 인겔하임 인터내셔날 게엠베하 | 세포 보유 장치 및 방법 |
| EP3480293A4 (en) * | 2016-06-30 | 2019-07-03 | FUJIFILM Corporation | Cell suspension membrane separation device and cell culture device |
| IL302693B2 (en) * | 2016-07-11 | 2025-10-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Methods and systems for growing cells in culture |
| CN111051494B (zh) | 2017-07-14 | 2024-03-29 | 康宁股份有限公司 | 用于手动或自动培养基交换的3d细胞培养容器 |
| US11857970B2 (en) | 2017-07-14 | 2024-01-02 | Corning Incorporated | Cell culture vessel |
| EP3652291B1 (en) | 2017-07-14 | 2021-12-29 | Corning Incorporated | Cell culture vessel |
| CN111094536B (zh) | 2017-07-14 | 2024-03-29 | 康宁股份有限公司 | 用于3d培养的细胞培养容器及培养3d细胞的方法 |
| EP3663390A4 (en) | 2017-09-06 | 2020-08-05 | FUJIFILM Corporation | PROCESS FOR MANUFACTURING A PRODUCT |
| US20200255785A1 (en) * | 2017-09-15 | 2020-08-13 | Bristol-Myers Squibb Company | Online biomass capacitance monitoring during large scale production of polypeptides of interest |
| CN111344558A (zh) | 2017-10-06 | 2020-06-26 | 龙沙有限公司 | 使用拉曼光谱法自动控制细胞培养 |
| EA202090740A1 (ru) | 2017-10-16 | 2020-07-07 | Ридженерон Фармасьютикалз, Инк. | Перфузионный биореактор и связанные с ним способы применения |
| KR20250111232A (ko) * | 2017-12-11 | 2025-07-22 | 암젠 인크 | 이중특이적 항체 생성물의 연속 제조 공정 |
| JP7432511B2 (ja) | 2018-03-08 | 2024-02-16 | レプリゲン・コーポレイション | 接線流深層濾過システムおよびそれを使用する濾過方法 |
| CN110241012B (zh) * | 2018-03-09 | 2022-11-01 | 嘉和生物药业有限公司 | 一种生物大分子上游分阶段截留的生产方法、生产模块及在生产中的应用 |
| CN111868249B (zh) * | 2018-03-19 | 2024-06-18 | 富士胶片株式会社 | 生产物的制造方法 |
| KR102819571B1 (ko) | 2018-05-25 | 2025-06-12 | 리플리겐 코포레이션 | 접선 유동 여과 시스템 및 방법 |
| CN108504562A (zh) * | 2018-06-21 | 2018-09-07 | 江苏澳创生物科技有限公司 | 一种发酵生产l-苏氨酸的系统及其应用 |
| JP7171696B2 (ja) | 2018-07-13 | 2022-11-15 | コーニング インコーポレイテッド | 相互接続されたウェルを有するマイクロプレートを備えた流体デバイス |
| WO2020013845A1 (en) | 2018-07-13 | 2020-01-16 | Corning Incorporated | Cell culture vessels with stabilizer devices |
| PL3649226T3 (pl) | 2018-07-13 | 2022-05-16 | Corning Incorporated | Płytki mikrodołkowe z boczną ścianką zawierającą powierzchnię dostarczającą płynną pożywkę |
| US12478571B2 (en) | 2018-12-17 | 2025-11-25 | Pontis Biologics, Inc. | Enzyme based compositions and methods for removing dental calculi |
| WO2020165873A1 (en) * | 2019-02-15 | 2020-08-20 | Oncosimis Biotech Private Limited | Method and system for enhanced continuous production, secretion and separation of recombinant polypeptides from bacteria |
| EP3962536A1 (en) * | 2019-04-29 | 2022-03-09 | Voyager Therapeutics, Inc. | Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors |
| JP2022537650A (ja) * | 2019-06-13 | 2022-08-29 | アムジエン・インコーポレーテツド | 生物製剤の製造における自動化された生物量に基づく灌流制御 |
| JP7680418B2 (ja) * | 2019-07-16 | 2025-05-20 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 高密度連続接種の細胞培養方法及びその応用 |
| EP4058547A1 (en) * | 2019-11-15 | 2022-09-21 | Lonza Ltd. | Process and system for producing an inoculum |
| CN116601279A (zh) | 2020-07-28 | 2023-08-15 | 思进股份有限公司 | 用于生产多肽的方法和系统 |
| BR112023021192A2 (pt) * | 2021-04-14 | 2023-12-19 | Genzyme Corp | Métodos de cultura por perfusão de uma célula mamífera |
| CA3266599A1 (en) | 2022-09-07 | 2024-11-07 | Quantitative Biosciences, Inc. | UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST |
| CN116179464A (zh) * | 2022-12-06 | 2023-05-30 | 无锡药明生物技术股份有限公司 | 提高培养液细胞密度和高密度细胞培养的方法 |
| WO2024192116A1 (en) * | 2023-03-14 | 2024-09-19 | Repligen Corporation | High viable cell density transfection |
| WO2024192171A1 (en) * | 2023-03-14 | 2024-09-19 | Sonnet BioTherapeutics, Inc. | Methods of making recombinant il-12 albumin binding domain fusion proteins |
| WO2024226439A1 (en) | 2023-04-24 | 2024-10-31 | Quantitative Biosciences, Inc. | Engineered biosensor strains of e. coli for continuous aerobic detection of analytes |
| CN121175432A (zh) * | 2023-05-31 | 2025-12-19 | 富士胶片株式会社 | 生产物的生产方法 |
| WO2025128343A1 (en) | 2023-12-11 | 2025-06-19 | Just-Evotec Biologics, Inc. | Protein expression using trans-splicing and split selectable markers |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US54544A (en) * | 1866-05-08 | Improvement in low-water detecters | ||
| JPS61199788A (ja) | 1985-02-28 | 1986-09-04 | Mitsubishi Rayon Co Ltd | 醗酵生成物の分離濃縮方法及び連続醗酵方法 |
| US5286646A (en) | 1985-11-25 | 1994-02-15 | Boehringer Mannheim Gmbh | Method for mammalian cell culture |
| GB8617646D0 (en) | 1986-07-18 | 1986-08-28 | Manchester Inst Science Tech | Recovery of biological material |
| US4806484A (en) | 1987-08-07 | 1989-02-21 | Igb Products, Ltd. | Perfusion airlift bioreactor |
| JPH0797982B2 (ja) | 1987-09-24 | 1995-10-25 | 東洋紡績株式会社 | 細胞培養装置 |
| US4921792A (en) * | 1987-11-27 | 1990-05-01 | Miles Inc. | Continuous cell dispersion, cultivation and substance recovery process |
| JPH01243985A (ja) | 1988-03-25 | 1989-09-28 | P C C Technol:Kk | 植物器官の培養法及びその培養槽 |
| US5595909A (en) | 1988-05-23 | 1997-01-21 | Regents Of The University Of Minnesota | Filter device |
| DE68917642T2 (de) | 1988-05-25 | 1995-02-09 | Teijin Ltd | Verfahren zur kontinuierlichen Züchtung von haftenden tierischen Zellen. |
| JPH02113896A (ja) * | 1988-10-24 | 1990-04-26 | Snow Brand Milk Prod Co Ltd | ヒト抗リシンモノクローナル抗体およびそれを分泌するハイブリドーマ |
| US5019512A (en) | 1989-03-17 | 1991-05-28 | Baxter International Inc. | Spin filter for removing substantially cell-free culture medium from suspension cell culture system |
| JPH0541984A (ja) * | 1990-09-07 | 1993-02-23 | Dow Chem Co:The | 攪拌容器における中空繊維においての細胞の増殖 |
| US5256294A (en) | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
| GB9118664D0 (en) | 1991-08-30 | 1991-10-16 | Celltech Ltd | Cell culture |
| JPH05153973A (ja) | 1991-12-03 | 1993-06-22 | Hitachi Ltd | 細胞培養方法及び装置 |
| US6204000B1 (en) | 1995-04-28 | 2001-03-20 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1 |
| JP2752918B2 (ja) * | 1995-05-16 | 1998-05-18 | ユーエイチティー株式会社 | 動物細胞のマイクロキャリア培養法 |
| US6001585A (en) | 1997-11-14 | 1999-12-14 | Cellex Biosciences, Inc. | Micro hollow fiber bioreactor |
| JP2997771B2 (ja) * | 1998-06-29 | 2000-01-11 | 金沢大学長 | 細胞の懸濁培養方法 |
| US8026096B1 (en) | 1998-10-08 | 2011-09-27 | Protein Sciences Corporation | In vivo active erythropoietin produced in insect cells |
| US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| CA2252972C (en) | 1998-11-26 | 2012-09-18 | National Research Council Of Canada | Serum-free production of recombinant proteins and adenoviral vectors |
| AU1997900A (en) | 1999-01-26 | 2000-08-18 | Schering-Plough Ltd | Propagation of bovine coronavirus in chinese hamster ovary cells |
| US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| IL145849A0 (en) * | 1999-04-15 | 2002-07-25 | Crucell Holland Bv | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
| EP1103610A1 (en) * | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
| JP2001149099A (ja) | 1999-11-26 | 2001-06-05 | Olympus Optical Co Ltd | 染色体異常解析のための有核細胞の標本作製方法 |
| US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
| US6168941B1 (en) | 2000-04-07 | 2001-01-02 | Genvec, Inc. | Method of producing adenoviral vector stocks |
| JP4138209B2 (ja) | 2000-06-29 | 2008-08-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラバスタチン含有組成物 |
| JP2002113896A (ja) | 2000-10-05 | 2002-04-16 | Seiko Epson Corp | 画像形成装置 |
| US7157273B2 (en) | 2001-04-17 | 2007-01-02 | Seiren Kabushiki Kaisha | Medium additives and media for culturing animal cells |
| DE10120835C2 (de) | 2001-04-27 | 2003-04-10 | Sifin Inst Fuer Immunpraeparat | Verfahren zur Herstellung von monoklonalen Antikörpern |
| CA2351156A1 (en) | 2001-07-04 | 2003-01-04 | Peter W. Zandstra | A bioprocess for the generation of pluripotent cell derived cells and tissues |
| DE60238863D1 (de) * | 2001-08-31 | 2011-02-17 | Bayer Schering Pharma Ag | Vorrichtung und verfahren zur fermentation in hohen zelldichten |
| ES2249616T3 (es) | 2001-09-05 | 2006-04-01 | Yamasa Corporation | Citidina-fosfocolina para el tratamiento de la neuropatia diabetica. |
| US20030054544A1 (en) * | 2001-09-14 | 2003-03-20 | Medcell Biologics, Inc. | Oxygen enriched bioreactor and method of culturing cells |
| JP2003219873A (ja) | 2002-01-24 | 2003-08-05 | Japan Science & Technology Corp | サケ科キングサーモン由来の不死化細胞 |
| US20030186335A1 (en) | 2002-03-28 | 2003-10-02 | National Institute Of Advanced Industrial Science And Technology | Monoclonal antibodies, hybridomas, cell isolation method, isolated cells and immunological diagnostic method |
| DE10237082B4 (de) | 2002-08-09 | 2014-12-31 | Sartorius Stedim Biotech Gmbh | Verfahren und Vorrichtung zur biotechnologischen Herstellung von Wertstoffen |
| EA008670B1 (ru) | 2003-05-09 | 2007-06-29 | Круселл Холланд Б.В. | Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции |
| JP2005041984A (ja) | 2003-07-22 | 2005-02-17 | Shin Kobe Electric Mach Co Ltd | 水架橋ポリオレフィン製シートの製造法 |
| EP1720972B1 (en) | 2004-03-05 | 2014-01-08 | DSM IP Assets B.V. | Process for cell culturing by continuous perfusion and alternating tangential flow |
| PL2343362T5 (pl) | 2006-07-14 | 2024-12-02 | Patheon Holdings I B.V. | Ulepszony proces hodowli komórek |
| JP2008308560A (ja) | 2007-06-13 | 2008-12-25 | Tohcello Co Ltd | 表面防汚性複合フィルムの製造方法 |
-
2005
- 2005-03-04 EP EP05715787.7A patent/EP1720972B1/en not_active Revoked
- 2005-03-04 EP EP10183651A patent/EP2308958A3/en not_active Withdrawn
- 2005-03-04 KR KR1020067018075A patent/KR101050585B1/ko not_active Ceased
- 2005-03-04 JP JP2007501239A patent/JP2007525984A/ja active Pending
- 2005-03-04 EP EP12186351A patent/EP2540815A1/en not_active Ceased
- 2005-03-04 CN CN201410601800.9A patent/CN104388324A/zh active Pending
- 2005-03-04 WO PCT/EP2005/002374 patent/WO2005095578A1/en not_active Ceased
- 2005-03-04 CN CN201410471955.5A patent/CN104593277A/zh active Pending
- 2005-03-04 CA CA002557046A patent/CA2557046A1/en not_active Withdrawn
- 2005-03-04 US US10/591,118 patent/US8206981B2/en active Active
- 2005-03-04 CN CNA2005800071754A patent/CN1930281A/zh active Pending
- 2005-03-04 PT PT57157877T patent/PT1720972E/pt unknown
- 2005-03-04 PL PL05715787T patent/PL1720972T3/pl unknown
- 2005-03-04 SI SI200531842T patent/SI1720972T1/sl unknown
- 2005-03-04 AU AU2005229359A patent/AU2005229359C1/en not_active Ceased
- 2005-03-04 DK DK05715787.7T patent/DK1720972T3/da active
- 2005-03-04 ES ES05715787.7T patent/ES2456015T3/es not_active Expired - Lifetime
-
2006
- 2006-08-28 IL IL177724A patent/IL177724A/en unknown
-
2010
- 2010-05-06 IL IL205606A patent/IL205606A/en unknown
-
2011
- 2011-02-22 JP JP2011036102A patent/JP2011125348A/ja active Pending
- 2011-11-28 JP JP2011259168A patent/JP2012090632A/ja active Pending
-
2012
- 2012-05-23 US US13/478,307 patent/US20130266985A1/en not_active Abandoned
-
2013
- 2013-10-14 US US14/052,878 patent/US9260695B2/en not_active Expired - Lifetime
-
2014
- 2014-01-31 JP JP2014016778A patent/JP5719947B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-26 JP JP2015209828A patent/JP2016039817A/ja active Pending
-
2017
- 2017-07-06 JP JP2017132997A patent/JP2017225443A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005229359B2 (en) | Process for cell culturing by continuous perfusion and alternating tangential flow | |
| US9670520B2 (en) | Process for the culturing of cells | |
| AU2013203461B2 (en) | Process for cell culturing by continuous perfusion and alternating tangential flow | |
| HK1179646A (en) | Perfusion cell culture | |
| HK1104189A (en) | Process for cell culturing by continuous perfusion and alternating tangential flow |